NASDAQ:EXAS - EXACT Sciences Stock Price, News, & Analysis

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

EXACT Sciences Co. (NASDAQ:EXAS) posted its earnings results on Thursday, February, 21st. The medical research company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.05. The medical research company earned $142.98 million during the quarter, compared to analyst estimates of $143 million. EXACT Sciences had a negative net margin of 38.54% and a negative return on equity of 23.58%. The business's quarterly revenue was up 63.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.18) EPS. View EXACT Sciences' Earnings History.

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, April 30th 2019. View Earnings Estimates for EXACT Sciences.

EXACT Sciences updated its FY 2019 earnings guidance on Thursday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $710-730 million, compared to the consensus revenue estimate of $704.35 million.

12 brokerages have issued 12 month price objectives for EXACT Sciences' stock. Their forecasts range from $84.00 to $120.00. On average, they anticipate EXACT Sciences' share price to reach $100.30 in the next year. This suggests a possible upside of 8.8% from the stock's current price. View Analyst Price Targets for EXACT Sciences.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

Headlines about EXAS stock have trended positive on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. EXACT Sciences earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.

Some companies that are related to EXACT Sciences include Iqvia (IQV), Incyte (INCY), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), Aduro BioTech (ADRO), NVIDIA (NVDA), Micron Technology (MU), Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alibaba Group (BABA), Medivation (MDVN) and Celgene (CELG).

EXACT Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include KAMES CAPITAL plc (0.42%), Hodges Capital Management Inc. (0.14%), Rhenman & Partners Asset Management AB (0.08%), Strs Ohio (0.05%), EFG Asset Management Americas Corp. (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own EXACT Sciences stock include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Hodges Capital Management Inc., State of Alaska Department of Revenue and Oakbrook Investments LLC. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Strs Ohio, EFG Asset Management Americas Corp., Bfsg LLC, Meeder Asset Management Inc., Nisa Investment Advisors LLC, Fulton Bank N.A. and WoodTrust Financial Corp. View Insider Buying and Selling for EXACT Sciences.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EXAS stock can currently be purchased for approximately $92.21.

EXACT Sciences has a market capitalization of $11.60 billion and generates $454.46 million in revenue each year. The medical research company earns $-175,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.

The official website for EXACT Sciences is http://www.exactsciences.com.

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.